Thiophosphamide (thiOTEF, Thiophosphamidum; list A ) is an antitumor agent. Applied with cancer of the ovary, breast cancer, inoperable cervical cancer, peritoneal mesothelioma, as well as with chronic lymphocytic leukemia, lymphogranulomatosis, chronic myeloid leukemia (with leukemic form), reticulosarcoma , lymphosarcoma.
Thiophosphamide is administered orally at 0.01–0.02 g every other day (3 times a week), an average course of 0.15–0.25 g per course, and also intramuscularly or intravenously at 0.01 g, in the first days daily or every other day, later in 2–5–7–14 days, for a course of treatment from 0.1 to 0.3 g.
Produced in hermetically sealed vials containing 0.01 and 0.02 g of thiophosphamide in powder form (for the preparation of ex tempore solutions) or tablets. See also Antineoplastic agents .